lenvatinib Mesylate
4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide methanesulfonate
CAS:857890-39-2
Purity:Not less than 98%
*The following content is generated by AI and is for reference only.
Overview
Lenvatinib Mesylate is a multi-targeted receptor tyrosine kinase inhibitor used in oncology. It is synthesized via methylation of lenvatinib base. Molecular Formula: C26H30F2N4O5S; CAS No.: 1279827-87-0.
Application
- Oncology Manufacturing: Production of oral tablets for differentiated thyroid cancer and renal cell carcinoma.
- Research & Development: Clinical trial supply for combination therapies targeting angiogenesis.
- Distribution: Bulk API supply to pharmaceutical contract manufacturing organizations (CMOs).
Precautions
Strictly store below -20°C in dry, light-resistant containers. Handle with appropriate PPE due to potential cytotoxicity. Contraindicated in pregnancy; requires rigorous waste disposal protocols.